You are here

Anti-Tumor Activity of Talabostat, Gemcitabine Combination To Be Determined in Phase 2 Trial

BOSTON--(BUSINESS WIRE)--June 23, 2005--Point Therapeutics, Inc. (NASDAQ:POTP) announced today that it has initiated a Phase 2 clinical trial of the Company's lead therapeutic compound, talabostat, for the treatment of metastatic pancreatic cancer. The study is designed to evaluate the anti-tumor activity of talabostat in combination with gemcitabine in patients with metastatic pancreatic cancer.

The trial design is a single-arm, two-stage study in up to 60 patients with metastatic pancreatic cancer. The primary clinical endpoint will be six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status.

"We are very pleased to have initiated our fifth Phase 2 talabostat study," said Don Kiepert, President and CEO of Point Therapeutics. "Our preclinical work with talabostat in combination with gemcitabine demonstrated encouraging results. Overall tumor rejection rates in mice increased to 45% when treated with the talabostat/gemcitabine combination as opposed to a 23% rejection with gemcitabine alone. We are hopeful that these results will translate into the clinical setting given the lack of options for patients facing pancreatic cancer."

According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2005 alone, 32,180 new cases of pancreatic cancer will be diagnosed and 31,800 people will die of the disease.

Source: Point Therapeutics, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs